Table 3.
Region | Treatment Group | Mean PSA (ng/mL)
|
|||
---|---|---|---|---|---|
N | Penultimate Visit | Last Visit | Increase | ||
| |||||
US | Atrasentan | 75 | 29.2 | 41.7 | 12.5 |
Placebo | 61 | 36.8 | 53.2 | 16.4 | |
| |||||
Non-US | Atrasentan | 61 | 65.9 | 86.1 | 20.3 |
Placebo | 50 | 79.6 | 98.2 | 18.6 |
Region | Treatment Group | Mean PSA (ng/mL)
|
|||
---|---|---|---|---|---|
N | Penultimate Visit | Last Visit | Increase | ||
| |||||
US | Atrasentan | 75 | 29.2 | 41.7 | 12.5 |
Placebo | 61 | 36.8 | 53.2 | 16.4 | |
| |||||
Non-US | Atrasentan | 61 | 65.9 | 86.1 | 20.3 |
Placebo | 50 | 79.6 | 98.2 | 18.6 |